Fraud Scandal Costs GSK $3 Billion

GlaxoSmithKline agreed to plead guilty and pay $3 billion to resolve criminal and civil allegations that it illegally promoted prescription drugs and failed to report safety data, the U.S. said.

China's Challenges: PMI Weakens to Lowest in Three Years
19:27 - China’s manufacturing conditions slipped to the weakest level in more than three years as sluggishness in the nation’s old growth drivers add to risks facing the government’s growth target. Bloomberg's Stephen Engle takes a look at the numbers on "Trending Business." (Source: Bloomberg)
  • What China’s PMI Report Tells Us About the Economy
  • China's 'Old Manufacturing' Suffering: IHS's Jackson
  • China Outlook: Long-Term Plays for Investors